Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes
Status:
Completed
Trial end date:
2017-05-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of ISIS 449884 (ISIS-GCGRRX) on Hepatic
Lipid and Glycogen Content in patients with Type 2 Diabetes being treated with Metformin.